Delivery Order SPE2DB24D1107-SPE2DB25FZFF3
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,541.08 for Restasis 0.05% Eye Emulsion (30-count units) on May 6, 2025, with an ultimate completion date of May 7, 2025. This firm fixed-price delivery order represents a non-competitive procurement under a larger indefinite delivery contract vehicle. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency awarded a $12,777.96 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Restasis 0.05% Eye Emulsion in 60-count units. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive procurement. Performance will be completed by July 29, 2025, with work performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order valued at $1,156.69 to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (30-count), a prescription ophthalmic medication commonly used to treat dry eye disease. This non-set-aside, competitively awarded contract utilized firm fixed pricing and is scheduled for completion by August 14, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $28,637.24 by the Defense Logistics Agency (DLA) on July 25, 2025, for the supply of Restasis 0.05% Eye Emulsion in 60-count units. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 28, 2025. The contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- On June 16, 2025, the Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $2,091.84 to AmerisourceBergen Drug Corp for the supply of Restasis 0.4ML in a 30-count package. This competitively awarded, firm fixed-price delivery order is scheduled for completion by June 17, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. Restasis is a prescription ophthalmic medication...
- The Defense Logistics Agency awarded a delivery order valued at $5,875.74 to AmerisourceBergen Drug Corp for RESTASIS 0.05% Eye Emulsion, a prescription ophthalmic medication used to treat dry eye disease. The contract, awarded on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a firm fixed-price delivery under a non-set-aside competitive procurement. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $5,990.32 to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (30-count units) on September 23, 2025, with an ultimate completion date of September 24, 2025. The contract utilizes firm fixed price terms with no set-aside designation, indicating competitive award through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,318.51 on July 28, 2025, for the supply of Restasis 0.05% eye emulsion (30 single-use vials). This firm fixed price delivery order, with an ultimate completion date of July 29, 2025, represents a small-value transaction issued under a larger indefinite delivery contract vehicle. The award was made through competitive procurement with no set-aside designation, and the product will be delivered to...
- The Defense Logistics Agency awarded a $1,293.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (60-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside contract was competitively awarded and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $1,349.15 to AmerisourceBergen Drug Corp for Restasis 0.05% eye emulsion (60 units) on August 5, 2025, with an ultimate completion date of August 6, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider headquartered in...
- SPE2DB24D1107Indefinite Delivery Contract
- SPE2DB24D1107-SPE2DB25FZFF3Delivery Order
The Defense Logistics Agency awarded a $23,799.46 delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (60 count) on May 8, 2025, with completion scheduled for May 9, 2025. This firm fixed-price contract, which was competitively awarded with no set-aside designation, will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Restasis is a prescription ophthalmic medication used to treat dry eye disease, representing part of AmerisourceBergen's ongoing supply of pharmaceutical products to the federal government's military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As one of the largest pharmaceutical distributors supporting federal medical procurement, AmerisourceBergen serves as a critical vendor for the Defense Health Agency and other government healthcare entities, providing an extensive portfolio of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $23.8k | 5/8/25 |